Ultime notizie per Organon (NYSE:OGN) Azioni

Organon

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Organon & Co

Origin Protocol - United States Dollar

OROGEN ROYALTIES INC by Orogen Royalties Inc.

Orogen Royalties Inc

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

CIBC maintains Clearway Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>) with a Outperformer and raises the price target from $33 to $34.

News

Price Target

Analyst Ratings

CWEN

CIBC Maintains Outperformer on Clearway Energy, Raises Price Target to $34

Published by the Federal Aviation Administration, the Special Federal Aviation Regulation&nbsp;establishes requirements for the safe and efficient integration of aircraft like Joby&#39;s into the nation&#39;s aviation system.
In doing so, it lays the groundwork necessary for Joby to launch commercial passenger service in the U.S., once the Company has received type certification of its aircraft.
Designed to carry a pilot and four passengers at speeds of up to 200 mph, the Joby aircraft will offer high-speed mobility with a small fraction of the noise produced by helicopters and zero operating emissions.

JOBY

Joby Aviation Welcomes Release Of New Rules Designed To Enable Aircraft Operation In US

CIBC analyst Mark Jarvi maintains Brookfield Renewable (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEP#NYSE">BEP</a>) with a Outperformer and raises the price target from $33 to $34.

CIBC Maintains Outperformer on Brookfield Renewable, Raises Price Target to $34

CIBC analyst Mark Jarvi maintains Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) with a Neutral and lowers the price target from $5.75 to $5.5.

CIBC Maintains Neutral on Algonquin Power, Lowers Price Target to $5.5

In connection with a reduction in force (RIF), Carlisha Robinson, former Chief Product Officer of Beyond, Inc. was terminated without cause effective October 22, 2024.&nbsp;
The Company estimates the RIF will result in annualized reduction of fixed costs by approximately $20 million.

BYON

Beyond Says Board Approved Reduction In Force Affecting Approximately 20% Of Its Workforce, Which Is Expected To Be Substantially Implemented In Q4 Of 2024 - Filing

Veritex Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBTX#NASDAQ">VBTX</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.55 by 7.27 percent. The company reported quarterly sales of $113.168 million which beat the analyst consensus estimate of $110.240 million by 2.66 percent. This is a 3.79 percent increase over sales of $109.035 million the same period last year.

Earnings

Earnings Beats

VBTX

Veritex Holdings Q3 2024 Adj. EPS $0.59 Beats $0.55 Estimate, Sales $113.168M Beat $110.240M Estimate

Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.63 by 11.11 percent. This is a 5.41 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $220.297 million which beat the analyst consensus estimate of $173.482 million by 26.99 percent. This is a 32.54 percent increase over sales of $166.210 million the same period last year.

RNST

Renasant Q3 2024 Adj. EPS $0.70 Beats $0.63 Estimate, Sales $220.297M Beat $173.482M Estimate

DBV Announces Positive Regulatory Updates for the Viaskin&#xAE; Peanut Patch in the United States and Europe
<ul>
<li>DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old&nbsp;</li>
<li>BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025</li>
<li>VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025&nbsp;&nbsp;</li>
<li>European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7 year-old indication in Europe</li>
<li>Company to host investor conference call at 5:00pm ET today &nbsp;</li>
</ul>
DBV Technologies (TRQX:<a href="https://www.benzinga.com/stock/DBVp#TRQX">DBVp</a>), a clinical-stage biopharmaceutical company, today announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV has agreed to guidance provided by the U.S. Food and Drug Administration (FDA) on a pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old and has also received scientific advice from the EMA on a 1 – 7 year-old indication in Europe. DBV intends to formalize the Accelerated Approval guidance provided by the FDA via submission of a meeting request.

Biotech

Global

General

DBVT

DBV Announces Regulatory Updates For The Viaskin Peanut Patch In The U.S. And Europe; BLA Submission Under Accelerated Approval Is Subject To Completion Of A 6-Month Supplemental Safety Study In Toddlers To Be Initiated In Q2 2025; VITESSE Phase 3 Study Evaluating The Viaskin Peanut Patch In Children Ages 4 – 7 Years-old Exceeded Enrollment Goals

WIIM

BYND

Beyond Meat shares are trading higher. The stock may be moving up in response to a CDC report linking an E. coli outbreak with McDonald's quarter pounders.

<ul>
<li>First and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50</li>
<li>Approval based on data from pivotal Phase 3 trial in adults at increased risk of lower respiratory tract disease caused by RSV</li>
</ul>

Pfizer Says FDA Approved RSV Vaccine ABRYSVO For Adults Aged 18 To 59 At Increased Risk For Disease

Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set forth in Listing Rule 5250(c)(1) (the "Rule") because it had not filed its Form 10-K for the year ended December 31, 2024 (the "Form 10-K"), and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the "Forms 10-Q"), respectively. Based on its review and the materials submitted on June 17, 2024 and August 27, 2024, Staff granted the Company an exception until October 14, 2024, to regain compliance with the Rule. Upon further review, Staff determined that the Company did not meet the terms of the exception. Specifically, the Company has not filed the either its Form 10-K or Forms 10-Q as required by the Rule. The Company will appeal Staff's determination to a Hearings Panel (the "Panel"), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

OCEA

Ocean Biomedical Announces Receipt Of Nasdaq Staff Determination Letter That It Did Not Comply With Nasdaq's Filing Requirements

Enphase Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) reported third-quarter financial results on Tuesday that came up short of analyst expectations. Here are the main <a href="https://www.benzinga.com/pressreleases/24/10/g41465834/enphase-energy-reports-financial-results-for-the-third-quarter-of-2024">highlights from the quarter</a>.
Q3 Earnings: Enphase Energy reported third-quarter revenue of $380.9 million, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $391.979 million. The solar company reported adjusted earnings of 65 cents per share, missing analyst estimates of 77 cents per share, according to&nbsp;<a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
U.S. revenue increased approximately 43% on a quarter-over-quarter basis due to higher shipments to distributors. Meanwhile, revenues in Europe fell approximately 15% quarter-over-quarter, driven by a &#8220;further softening&#8221; in European demand.
Enphase shipped 172.9 megawatt hours of IQ batteries in the quarter and shipped approximately 1,176,000 microinverters from its contract manufacturing facilities in the U.S. The company also highlighted the launch of its <a href="http://benzinga.com/topic/ai">AI</a>-based software for energy optimization in the quarter.
&#8220;We began shipping IQ8HC microinverters with higher domestic content, produced at our contract manufacturing facilities in the U.S. We expect to begin shipping our commercial microinverters, and batteries with higher domestic content, produced at our U.S. contract manufacturing facilities in the fourth quarter of 2024,&#8221; the company said.
Enphase said it generated&nbsp;$170.1&nbsp;million&nbsp;in cash flow from operations and $161.3 million in free cash flow during the quarter. The company ended the quarter with $1.77 billion in cash, cash equivalents&nbsp;and marketable securities.
Related Link: <a href="https://www.benzinga.com/news/24/10/41454966/this-first-solar-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a>
Outlook:&nbsp;Enphase expects fourth-quarter revenue to be in the range of $360 million to $400 million. The company anticipates third quarter gross margin of 47% to 50%, or 49% to 52% on an adjusted basis.
Management will hold a conference call to further discuss these results with analysts and investors at 4:30 p.m. ET.
ENPH Price Action: <a href="https://www.benzinga.com/quote/ENPH" target="_blank" rel="noreferrer noopener">Enphase shares</a> were down 7.31% in after-hours, trading at $85.20 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41461948/boeing-stock-braces-for-bumpy-q3-landing">Boeing Stock Braces For Bumpy Q3 Landing</a></li>
</ul>
Photo: Courtesy of Enphase Energy.

Guidance

After-Hours Center

Movers

ENPH

Enphase Energy Stock Slides On Q3 Earnings Miss: US Revenue Jumps, European Revenue Falls On 'Further Softening' Demand

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 18.66% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 11.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 3.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MASI

How Is The Market Feeling About Masimo?

Universal Health Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) short percent of float has fallen 9.14% since its last report. The company recently reported that it has 1.41 million shares sold short, which is 3.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Universal Health Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629914_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Universal Health Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Universal Health Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Universal Health Servs's peer group average for short interest as a percentage of float is 5.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Universal Health Servs's Recent Short Interest

A recent poll shows that 50% of Utahns now support the legalization of adult-use recreational marijuana, reflecting a significant shift in public opinion. 
The survey, conducted by Noble Predictive Insights for the Utah Patients Coalition, highlights evolving attitudes just six years after the state legalized medical marijuana.&nbsp;
Utah's cannabis market, with its underserved demand due to strict regulations, high prices and limited access, hints at significant untapped potential for investors if rules evolve. 
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Key Poll Findings</h3>
The poll shows that 50% of Utah voters support recreational cannabis legalization, while 38% prefer medical cannabis only and 9% believe it should remain illegal. Younger voters, aged 18-34, overwhelmingly favor legalization at 60%, while only 29% of those over 65 support it.
<h3 class="wp-block-heading">Shifting Attitudes And The Medical Cannabis Program</h3>
Desiree Hennessy, executive director of the Utah Patients Coalition, noted growing acceptance of recreational cannabis. She pointed to the evolution of the medical marijuana program, established after voters approved Proposition 2 in 2018, as part of the shift in attitudes. However, issues like pricing and access still push many patients to seek weed from other states or through illegal markets.
Rep. Jennifer Dailey-Provost <a href="https://www.fox13now.com/news/politics/new-poll-shows-half-of-utahns-now-support-legalizing-recreational-marijuana">emphasized</a> that high prices in Utah's medical program are driving patients elsewhere. She plans to introduce legislation in 2025 to improve pricing transparency for patients.
<h3 class="wp-block-heading">Cannabis Regulations In Utah</h3>
Utah maintains strict regulations on cannabis use, allowing only medical marijuana under the Utah Medical Cannabis Act. Smoking is prohibited, with legal options limited to capsules, tinctures and vaporized products. Penalties for possessing recreational cannabis remain severe, with fines of up to $1,000 for small amounts. Many patients still look to out-of-state sources to escape high costs.
Several companies, including Dragonfly Wellness, the first medical cannabis dispensary in Salt Lake City, are active in Utah's regulated medical cannabis market. Multi-state operators such as Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Columbia Care (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CCHWF#OTC">CCHWF</a>), and Bloom Medicinals are also <a href="https://www.benzinga.com/markets/cannabis/24/06/39256426/heres-how-to-enhance-marijuana-therapies-kindlymd-and-curaleaf-collab-provide-more-resources-and">licensed to operate in the state</a>, contributing to the network of 14 medical dispensaries. Utah recently issued its 15th medical cannabis pharmacy license, further expanding its regulated market​. 
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/10/41348741/why-pennsylvanias-gop-districts-are-embracing-weed-the-cannabis-revolution-you-didnt-see-coming"> Why Pennsylvania&#8217;s GOP Districts Are Embracing Weed: The Cannabis Revolution You Didn&#8217;t See Coming</a>
<h3 class="wp-block-heading">Market Insights For Cannabis Investors</h3>
According to the March 2024 report from the Utah Department of Health and Human Services, Utah&#8217;s medical cannabis market faces a competitive landscape due to <a href="https://www.benzinga.com/markets/cannabis/24/02/37269098/utah-considers-defunding-agencies-that-discriminate-against-medical-marijuana-patients-arizona-w">cross-price pressures from neighboring states </a>with mature adult-use cannabis markets.
As of March 2024, Utah had 83,421 registered medical cannabis patients, primarily treating pain, PTSD, and nausea. Utah's medical market captures 40.13% of cannabis demand, with patients sourcing an average of 4.01 grams per month from medical dispensaries.&nbsp;
However, when it comes to purchasing decisions for medical cannabis in Utah, price is the most important factor for 28% of patients, followed by THC/CBD content at 22%. Price remains a dominant factor, consistently ranking higher than other attributes in patient decision-making. 
Price discrepancies with neighboring states are driving patients to look for other options, with Utah residents willing to pay $12.15 per gram, compared to $8.37 in Colorado and $8.58 in <a href="https://www.benzinga.com/topic/nevada-cannabis">Nevada</a>. Monthly spending averages $109.10, close to the national average.
The <a href="https://ag.utah.gov/wp-content/uploads/2024/04/Utah-Medical-Cannabis-Market-Analysis_2023.pdf">report </a>from the Department of Health and Human Services found that 25.5% of medical cannabis patients traveled out of state for cannabis in the past month, with 58.53% going to<a href="https://www.benzinga.com/topic/colorado-cannabis"> Colorado </a>and Nevada.&nbsp;
Meanwhile, 26.6% of non-patients also traveled out of state for cannabis. There was only a 1.1% difference in travel frequency between medical and non-medical users, with non-patients slightly more likely to travel.
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/10/41382006/hemp-thrives-in-texas-shops-near-schools-why-this-company-bet-on-the-countrys-most-regulated-can"> Hemp Thrives In Texas Shops Near Schools: Why This Company Bet On The Country&#8217;s Most Regulated Cannabis Market</a>
<h3 class="wp-block-heading">Future Of Recreational Cannabis In Utah</h3>
Despite growing support, Utah's path to recreational cannabis legalization remains uncertain. Dailey-Provost notes that federal descheduling may be necessary before any significant political movement occurs. For now, Utah is surrounded by states with legal recreational markets, which could add pressure for future changes.
Read Next:<a href="https://www.benzinga.com/general/biotech/24/10/41394513/sold-out-before-hitting-shelves-why-did-ayr-wellness-snatch-up-this-local-cannabis-brand"> Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?</a>

Cannabis

Government

Regulations

Retail Sales

CCHWF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

Is Utah Ready For Legal Weed? Half The State Says Yes -What's The Market Potential?

Macro Economic Events

Econ #s

Economics

API Weekly Crude Oil Stock Build Of 1.643 Barrels Vs Build Of 0.700M Barrel Est.; Draw Of 1.580M Barrels Prior

MTDR

Matador Resources shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 production guidance.

WFRD

Weatherford shares are trading higher following Q3 financial results.

Wheels Up Experience Entered Into Agreement To Acquire Grandview Aviation Entire Fleet Of 17  Phenom 300 And Phenom 300E Aircraft At $105M

VICR

Vicor shares are trading higher after the company reported better-than-expected Q3 financial results.

Evercore ISI analyst Umer Raffat maintained a Buy rating on Organon (OGN – Research Report) today. The company's shares opened today at $20.51. Raf...

Evercore ISI Sticks to Their Buy Rating for Organon (OGN)

Barclays analyst Balaji Prasad maintained a Buy rating on Organon (OGN – Research Report) today and set a price target of $26.00. The company's sha...

Barclays Keeps Their Buy Rating on Organon (OGN)

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of $18.00. Terence ...

Assessing Organon's Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Japan's Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Nippon Shinyaku will pay $20 million upfront and up to $715 million in milestones, plus royalties.

Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy

Organon: A Surprising Deal

Organon reports positive phase 3 results on Roche Perjuta biosimilar

Organon reports positive phase 3 results on Roche Perjeta biosimilar

EU regulators reviewing safety of finasteride, dutasteride

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Organon (OGN – Research Report) today and set a price target of $18.00. The compan...

Organon (OGN) Gets a Hold from Morgan Stanley

BAYRY

BAYZF

CAPR

MRNA

NPPNY

RHHBY

ROIV

Press Releases

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

Organon Reports Results for the Second Quarter Ended June 30, 2024

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

ROIVW

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Organon

Notizie

Ultime notizie per Organon (NYSE:OGN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO